A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or piatinum-resistant ovarian cancer (OC)

Colin D. Weekes; Laetitia E. Lamberts; Mitesh J. Borad; Johannes Voortman; Robert R. McWilliams; Jennifer Robinson Diamond; Elisabeth De Vries; Henk M. W. Verheul; Christopher Hanyoung Lieu; Huibin Yue; Yulei Wang; Suzie Scales; Divya Samineni; Katie Wood; Flavia Brunstein; Daniel J. Maslyar; George P. Kim

A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or piatinum-resistant ovarian cancer (OC)

Colin D. Weekes
, Laetitia E. Lamberts
, Mitesh J. Borad
, Johannes Voortman
, Robert R. McWilliams
, Jennifer Robinson Diamond
, Elisabeth De Vries
, Henk M. W. Verheul
, Christopher Hanyoung Lieu
, Huibin Yue
, Yulei Wang
, Suzie Scales
, Divya Samineni
, Katie Wood
, Flavia Brunstein
, Daniel J. Maslyar
, George P. Kim

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Journal	Journal of clinical oncology
Volume	32
Issue number	15
Publication status	Published - 20 May 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Weekes, C. D., Lamberts, L. E., Borad, M. J., Voortman, J., McWilliams, R. R., Diamond, J. R., De Vries, E., Verheul, H. M. W., Lieu, C. H., Yue, H., Wang, Y., Scales, S., Samineni, D., Wood, K., Brunstein, F., Maslyar, D. J., & Kim, G. P. (2014). A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or piatinum-resistant ovarian cancer (OC). Journal of clinical oncology, 32(15).

@article{911107b98dda4cae90fc9fbe7030738e,

title = "A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or piatinum-resistant ovarian cancer (OC)",

author = "Weekes, \{Colin D.\} and Lamberts, \{Laetitia E.\} and Borad, \{Mitesh J.\} and Johannes Voortman and McWilliams, \{Robert R.\} and Diamond, \{Jennifer Robinson\} and \{De Vries\}, Elisabeth and Verheul, \{Henk M. W.\} and Lieu, \{Christopher Hanyoung\} and Huibin Yue and Yulei Wang and Suzie Scales and Divya Samineni and Katie Wood and Flavia Brunstein and Maslyar, \{Daniel J.\} and Kim, \{George P.\}",

year = "2014",

month = may,

day = "20",

language = "English",

volume = "32",

journal = "Journal of clinical oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "15",

}

Weekes, CD, Lamberts, LE, Borad, MJ, Voortman, J, McWilliams, RR, Diamond, JR, De Vries, E, Verheul, HMW, Lieu, CH, Yue, H, Wang, Y, Scales, S, Samineni, D, Wood, K, Brunstein, F, Maslyar, DJ & Kim, GP 2014, 'A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or piatinum-resistant ovarian cancer (OC)', Journal of clinical oncology, vol. 32, no. 15.

A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or piatinum-resistant ovarian cancer (OC). / Weekes, Colin D.; Lamberts, Laetitia E.; Borad, Mitesh J. et al.
In: Journal of clinical oncology, Vol. 32, No. 15, 20.05.2014.

Research output: Contribution to journal › Meeting Abstract › Academic

TY - JOUR

T1 - A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or piatinum-resistant ovarian cancer (OC)

AU - Weekes, Colin D.

AU - Lamberts, Laetitia E.

AU - Borad, Mitesh J.

AU - Voortman, Johannes

AU - McWilliams, Robert R.

AU - Diamond, Jennifer Robinson

AU - De Vries, Elisabeth

AU - Verheul, Henk M. W.

AU - Lieu, Christopher Hanyoung

AU - Yue, Huibin

AU - Wang, Yulei

AU - Scales, Suzie

AU - Samineni, Divya

AU - Wood, Katie

AU - Brunstein, Flavia

AU - Maslyar, Daniel J.

AU - Kim, George P.

PY - 2014/5/20

Y1 - 2014/5/20

M3 - Meeting Abstract

SN - 0732-183X

VL - 32

JO - Journal of clinical oncology

JF - Journal of clinical oncology

IS - 15

ER -